BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Crean D, Godson C. Specialised lipid mediators and their targets. Seminars in Immunology 2015;27:169-76. [DOI: 10.1016/j.smim.2015.05.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Cummins EP, Crean D. Hypoxia and inflammatory bowel disease. Microbes and Infection 2017;19:210-21. [DOI: 10.1016/j.micinf.2016.09.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
2 Wei J, Gronert K. Eicosanoid and Specialized Proresolving Mediator Regulation of Lymphoid Cells. Trends Biochem Sci 2019;44:214-25. [PMID: 30477730 DOI: 10.1016/j.tibs.2018.10.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
3 Du Y, Rong L, Cong Y, Shen L, Zhang N, Wang B. Macrophage polarization: an effective approach to targeted therapy of inflammatory bowel disease. Expert Opin Ther Targets 2021;25:191-209. [PMID: 33682588 DOI: 10.1080/14728222.2021.1901079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zahoor I, Giri S. Specialized Pro-Resolving Lipid Mediators: Emerging Therapeutic Candidates for Multiple Sclerosis. Clin Rev Allergy Immunol 2021;60:147-63. [PMID: 32495237 DOI: 10.1007/s12016-020-08796-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 de Gaetano M, Tighe C, Gahan K, Zanetti A, Chen J, Newson J, Cacace A, Marai M, Gaffney A, Brennan E, Kantharidis P, Cooper ME, Leroy X, Perretti M, Gilroy D, Godson C, Guiry PJ. Asymmetric Synthesis and Biological Screening of Quinoxaline-Containing Synthetic Lipoxin A4 Mimetics (QNX-sLXms). J Med Chem 2021;64:9193-216. [PMID: 34138563 DOI: 10.1021/acs.jmedchem.1c00403] [Reference Citation Analysis]
6 Sansbury BE, Spite M. Resolution of Acute Inflammation and the Role of Resolvins in Immunity, Thrombosis, and Vascular Biology. Circ Res 2016;119:113-30. [PMID: 27340271 DOI: 10.1161/CIRCRESAHA.116.307308] [Cited by in Crossref: 91] [Cited by in F6Publishing: 48] [Article Influence: 18.2] [Reference Citation Analysis]
7 Aslan M, Kıraç E, Yılmaz Ö, Ünal B, Konuk E, Özcan F, Tuzcu H. Effect of tauroursodeoxycholic acid on PUFA levels and inflammation in an animal and cell model of hepatic endoplasmic reticulum stress. Hum Exp Toxicol 2018;37:803-16. [DOI: 10.1177/0960327117734621] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
8 Fairman G, Robichaud S, Ouimet M. Metabolic Regulators of Vascular Inflammation. Arterioscler Thromb Vasc Biol 2020;40:e22-30. [PMID: 31967905 DOI: 10.1161/ATVBAHA.119.312582] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 de Gaetano M, Butler E, Gahan K, Zanetti A, Marai M, Chen J, Cacace A, Hams E, Maingot C, Mcloughlin A, Brennan E, Leroy X, Loscher CE, Fallon P, Perretti M, Godson C, Guiry PJ. Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A4 mimetics (sLXms). European Journal of Medicinal Chemistry 2019;162:80-108. [DOI: 10.1016/j.ejmech.2018.10.049] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
10 Pascoal LB, Palma BB, Chaim FHM, de Castro MM, Damázio TA, Franceschini APMF, Milanski M, Velloso LA, Leal RF. New translational and experimental insights into the role of pro-resolving lipid mediators in inflammatory bowel disease. World J Exp Med 2022; 12(1): 1-15 [DOI: 10.5493/wjem.v12.i1.1] [Reference Citation Analysis]
11 Hughes MF, Lenighan YM, Godson C, Roche HM. Exploring Coronary Artery Disease GWAs Targets With Functional Links to Immunometabolism. Front Cardiovasc Med 2018;5:148. [PMID: 30460244 DOI: 10.3389/fcvm.2018.00148] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Doyle R, Godson C, Brennan E. Promoting resolution in kidney disease: are we nearly there yet? Curr Opin Nephrol Hypertens 2020;29:119-27. [PMID: 31599748 DOI: 10.1097/MNH.0000000000000558] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Waindok P, Janecek-Erfurth E, Lindenwald D, Wilk E, Schughart K, Geffers R, Balas L, Durand T, Rund KM, Schebb NH, Strube C. Multiplex profiling of inflammation-related bioactive lipid mediators in Toxocara canis- and Toxocara cati-induced neurotoxocarosis. PLoS Negl Trop Dis 2019;13:e0007706. [PMID: 31557153 DOI: 10.1371/journal.pntd.0007706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Abdolmaleki F, Kovanen PT, Mardani R, Gheibi-Hayat SM, Bo S, Sahebkar A. Resolvins: Emerging Players in Autoimmune and Inflammatory Diseases. Clin Rev Allergy Immunol 2020;58:82-91. [PMID: 31267470 DOI: 10.1007/s12016-019-08754-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]